1. Improving CAR T-Cell Persistence
   Violena Pietrobon et al, 2021, International Journal of Molecular Sciences CrossRef
2. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
   null null et al, 2021, Cochrane Database of Systematic Reviews CrossRef
3. CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response
   Augusto Rojas-Martinez et al, 2022, Current Gene Therapy CrossRef
4. Monitoraggio delle complicanze da tossicità nei pazienti sottoposti a CAR-T: studio osservazionale, prospettico
   Francesca Palmisano et al, 2022, Working Paper of Public Health CrossRef
5. IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro
   Huihui Zhang et al, 2022, Human Vaccines & Immunotherapeutics CrossRef
6. Targeted Immunotherapies in Gastrointestinal Cancer: From Molecular Mechanisms to Implications
   Ding-Kang Wang et al, 2021, Frontiers in Immunology CrossRef
7. Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis
   Sabine Seidel et al, 2023, Neurological Research and Practice CrossRef
8. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels
   Ying Li et al, 2024, Frontiers in Immunology CrossRef
9. Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor‐T cell therapy
   Cecilia C. S. Yeung et al, 2024, European Journal of Haematology CrossRef
10. IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma
    Sheridan L. Swan et al, 2023, Frontiers in Immunology CrossRef
11. Molecular Aspects of Resistance to Immunotherapies—Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma
    Aleksandra Kusowska et al, 2022, International Journal of Molecular Sciences CrossRef
12. Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells
    Ali Hosseini Rad S. M. et al, 2021, Cancers CrossRef
13. PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report
    Chenggong Li et al, 2021, Frontiers in Immunology CrossRef
14. Cytokine release syndrome after CAR T-cell therapy: a review of the literature and our experience
    B Čemusová, 2022, Anesteziologie a intenzivní medicína CrossRef
15. Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy
    Yasmin Jenkins et al, 2021, Antibodies CrossRef
16. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
    Leo I. Gordon et al, 2023, Oncotarget CrossRef
17. Efficacy and Safety of Dual-Targeting Chimeric Antigen Receptor-T Therapy for Relapsed or Refractory B Cell Lymphoid Malignancies: A Systematic Review and Meta-Analysis
    Min Yu et al, 2023, Human Gene Therapy CrossRef
18. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis
    Irit Avivi et al, 2022, Annals of Hematology CrossRef